Kimia Biosciences Intrinsic Value
KIMIABL Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹37.40 | ₹29.92 - ₹44.88 | +34.7% | EPS: ₹1.70, Sector P/E: 22x |
| Book Value Method | asset | ₹40.00 | ₹36.00 - ₹44.00 | +44.1% | Book Value/Share: ₹20.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹55.52 | ₹49.97 - ₹61.07 | +100.0% | Revenue/Share: ₹254.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹55.52 | ₹49.97 - ₹61.07 | +100.0% | EBITDA: ₹20.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹69.40 | ₹55.52 - ₹83.28 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹10.88 | ₹9.79 - ₹11.97 | -60.8% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹25.53 | ₹22.98 - ₹28.08 | -8.0% | Revenue Growth: 0.2%, Adj P/E: 15.0x |
| ROE Based Valuation | profitability | ₹55.52 | ₹49.97 - ₹61.07 | +100.0% | ROE: 80.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹27.66 | ₹24.89 - ₹30.43 | -0.4% | EPS: ₹1.70, BVPS: ₹20.00 |
Want to compare with current market value? Check KIMIABL share price latest .
Valuation Comparison Chart
KIMIABL Intrinsic Value Analysis
What is the intrinsic value of KIMIABL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Kimia Biosciences (KIMIABL) is ₹40.00 (median value). With the current market price of ₹27.76, this represents a +44.1% variance from our estimated fair value.
The valuation range spans from ₹10.88 to ₹69.40, indicating ₹10.88 - ₹69.40.
Is KIMIABL undervalued or overvalued?
Based on our multi-method analysis, Kimia Biosciences (KIMIABL) appears to be trading below calculated value by approximately 44.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.95 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 11.10 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 80.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 14.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.14x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Kimia Biosciences
Additional stock information and data for KIMIABL
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹21 Cr | ₹19 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹15 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-7 Cr | ₹-9 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹8 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹6 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |